Cough in adult cystic fibrosis: diagnosis and response to fundoplication
© Fathi et al; licensee BioMed Central Ltd. 2009
Received: 03 September 2008
Accepted: 18 January 2009
Published: 18 January 2009
Gastroesophageal reflux is one of the most common causes of chronic cough in the general population. Reflux occurs frequently in patients with cystic fibrosis (CF). We undertook laparoscopic Nissen fundoplication in adult CF patients with a clinical diagnosis of reflux cough who had failed conventional medical therapies.
We determined the response to the surgical route in the treatment of intractable reflux cough in CF.
Patients with refractory cough were assessed by 24 h pH monitoring and oesophageal manometry. Pre-and post-operation cough, lung function and exacerbation frequency were compared. Cough was assessed by the Leicester Cough Questionnaire (LCQ), lung function by spirometry and exacerbation frequency was defined by comparing the postoperative epoch with a similar preoperatively.
Significant abnormalities of oesophageal function were seen in all patients studied. 6 patients (2 females), with the mean age of 34.5 years consented to surgery. Their mean number of reflux episodes was 144.4, mean DeMeester score was 39.2, and mean lower oesophageal sphincter pressure 12.4 mmHg. There was a small change in the FEV1 from 1.03 L to 1.17 (P = 0.04), and FVC improved from 2.62 to 2.87 (P = 0.05). Fundoplication lead to a marked fall in cough with the total LCQ score increasing from 11.9 to 18.3 (P = 0.01). Exacerbation events were reduced by 50% post operatively.
Whilst there is an obvious attention to respiratory causes of cough in CF, reflux is also a common cause. Fundoplication is highly effective in the control of reflux cough in CF. Significant reduction in exacerbation frequency may indicate that reflux with possible aspiration is a major unrecognised contributor to airway disease.
Cystic fibrosis (CF) is a multisystem disease which impacts the digestive system, sweat glands, and the reproductive tract, but progressive pulmonary insufficiency continues to be major cause of morbidity and mortality. The main respiratory manifestations include chronic bacterial colonisation, cough, bronchiectasis, haemoptysis, emphysema, and pneumothorax. As the disease progresses chronic cough becomes a universal symptom, reported by virtually all patients.
Gastroesophageal reflux, which is increasingly recognised as one of the most common causes of chronic cough in general population, occurs frequently in patients with CF. About one in five newly diagnosed infants with cystic fibrosis have pathological reflux, and a higher frequency (25–55%) has been previously reported in children over 1 year old.[5, 6] Similarly, high rates of reflux symptoms, diminished lower oesophageal sphincter pressure and acid reflux are reported in adult CF patients. However, because of the understandable focus on airway disease in CF, reflux as a potential aetiology of chronic cough is often unconsidered. Fortunately, the symptomatology of reflux induced cough allows the clinician to identify cough of gastroesophageal origin.
The medical treatment of oesophageal reflux causing cough is challenging, particularly in the presence of non-acid reflux. In contrast to the treatment of gastroesophageal reflux disease (GORD) causing heart burn, where acid is a vital component, patients with chronic cough frequently fail to respond to full acid suppression with proton pump inhibitors (PPI) and H2 blockers. In the treatment of resistant chronic cough, Nissen fundoplication has been shown to be an effective tool.
Class of drug
Duration of Therapy
Proton pump inhibitor BD + H2-receptor antagonists (Ranitidine) nocte
At least 2 months
Dopamine receptor antagonist (Metoclopramide, Domperidone) TDS
Cough Suppressant (Morphine, Disofrol)
GABA agonist (Baclofen) TDS
30 adult patients with CF diagnosed on the basis of clinical presentations and confirmed by sweat tests or genetic investigation, are under the care of the Hull adult CF unit. 18 patients were considered to have symptoms of reflux cough based on a semi-structured questionnaire, (Appendix 1)  and prescribed standard medical treatment. We report our experience in 6 patients who consented to undergo LNF following the failure of maximal medical therapy to control reflux symptoms, particularly chronic cough.
For this study ethical approval was waived by the ethics committee of Hull and East Riding, UK. (Letter dated 19th of June 2008)
Oesophageal motility was assessed by solid-state manometry. Ambulatory 24 hr oesophageal pH was used to assess the presence of gastroesophageal reflux. Intra oesophageal pH was measured at a level of 5 cm above the pre determined (via oesophageal manometry) upper border of the lower oesophageal sphincter (LOS), and presented as DeMeester score
Laparoscopic fundoplication was performed in a standard fashion under general anaesthesia with full muscle relaxation using a five port technique. In every case the oesophageal hiatus was fully dissected and the oesophagus mobilised. At least one non absorbable suture was placed to approximate the crura posterior to the oesophagus and to minimise the risk of post-operative herniation. In cases where there was a large pre-existing hiatal defect, additional posterior crural sutures were placed as required. In most cases there was no obvious hiatus hernia demonstrated at surgery. Calibration of the oesophageal hiatus was clinical but in cases of doubt a 56 Fr endoluminal bougie was available to calibrate the appropriate size.
Our primary outcome measure was the change in cough as assessed by self-administered Leicester Cough Questionnaire (LCQ). Pre- and post-operative changes in spirometry and exacerbation rate as defined by an event requiring antibiotics (oral or IV), were secondary endpoints. Results are expressed as means and standard deviations (SD), and the comparisons pre and post- operatively were made by paired t-test with 95% confidence interval (CI), using SPSS software version 13.
Demeester score, esophageal ph and manometry studies pre-operation
Demographics and pre-operation assessments
LOS Resting Pressure 15–30 mmHg
% of time pH > 4
Reflux Episodes NL < 50
DeMeester Score NL < or = 14.7
Leicester cough questionnaire (LCQ)
Patients were asked to report the severity of their symptom using LCQ pre- and post-operatively. LCQ results were calculated by the sum of scores from each of its three domains. Total LCQ score improved significantly from 11.9 (± 3.2) to 18.3 (± 1.2), P = 0.01 (CI: 2.2 to 10.4).
Forced expiratory volume in one second (FEV1) increased from a mean of 1.03L (± 0.32) to 1.17L (± 0.41), P = 0.04 (95%CI = 0 to 0.25), and forced vital capacity (FVC) improved from a mean of 2.62L (± 0.88) to 2.87L (± 0.96) and P = 0.05.
Cough is the commonest symptom of medical importance. Chronic cough is a frequent symptom in general population with the incidence of 12%. Whilst airway disease, particularly when characterized by eosinophilic inflammation, can commonly cause cough, gastroesophageal reflux is increasingly recognised as an important precipitant of coughing paroxysms. We have recently described characteristic features in the clinical history which point to reflux as a cause of cough. Associations such as cough on eating, and post-prandially, cough precipitated by a change of posture or on rising in the morning, can be explained by the known physiology of the lower oesophageal sphincter. Extra-oesophageal manifestations such as dysphonia, and an unpleasant taste in the mouth are also important clinical pointers to reflux as a cause of coughing.
Cough is one of the characteristic symptoms of CF, initially presenting as pulmonary exacerbations. In a study of objective cough frequency in 14 CF children with exacerbations, cough rates per hour were reported as 18.2 during the day and 5.8 during the night.  Another study of 20 CF adults admitted with exacerbations demonstrated rates of 21.2 during the day and 4.8 at night.
In some patients with CF, cough becomes a persistent chronic symptom. Patients will describe two sorts of cough. One productive and associated with exacerbations and a second dry cough usually characterised by irritation in the throat. We sought the clinical history of reflux cough in our patients with chronic cough and were struck by the high incidence of reflux associated features. As a result, we invited them to undergo oesophageal function studies.
In the normal western population, excessive acid reflux is a common finding with the prevalence of between 10 to 20%. It is well recognised that CF patients have excessive incidence of acid reflux leading to high frequency of the classic symptoms of heart burn and dyspepsia. A recent study has shown that CF patients with demonstrable reflux have a high incidence of increased bile acids in saliva, and they have definitive evidence of gastric aspiration, confirmed by the presence of bile acids in bronchoalveolar lavage fluid. Moreover, significant reductions in FEV1 and FVC, and progression of pulmonary disease due to reflux have been reported previously.
Suggested mechanisms of excessive reflux included abnormalities of pancreatic and duodenal function leading to increased enteroglucagon levels, and hence delayed gastric emptying. Gastric acid secretion may be excessive. Reflux may also be facilitated by oesophageal dysmotility, the head-down position during respiratory treatment or certain respiratory medications (e.g. theophylline). The mechanical disruption of the lower oesophageal sphincter as a result of alterations in the shape of chest wall and flattening of the diaphragm in chronic lung disease can also precipitate reflux.
In all of our studied patients acid reflux was confirmed. The recommended strategy in treatment of reflux cough is therapeutic trials; starting with high dose proton pump inhibitors plus ranitidine (so called full acid suppression), to pro-motility agents (metoclopramide or domperidone) and cough suppressants such as low dose opioid. On therapy, heart burn and dyspepsia were improved, but in contrast there was no or little change in the degree of the cough.
Fundoplication has been reported as extremely effective in the treatment and management of reflux symptoms. It has been shown to be effective in the control of cough in patients with reflux (acid or non-acid), with or with out primary respiratory problems.[27, 28] In our study, the beneficial effects of fundoplication in the form of reduced cough and improvement of voice were reported by the patients and noticed by the physician on the first post operative day. A formal assessment by LCQ of the longer term effects on quality of life showed a consistent benefit of the procedure. The increase in LCQ of 6 points in our patients is the highest clinically significant improvement reported, and nearly was double that seen from the effect of opiates in chronic cough. The changes in spirometrically assessed lung function were small, and while of borderline statistically significance probably do not represent clinically important benefit. What was surprising was the marked reduction in exacerbation rate as defined by the need for antibiotic therapy. This is a non-controlled study and therefore regression to the mean or a placebo effect can not be discounted, however the halving of the incidence may suggest an important affect of fundoplication on pulmonary exacerbations. It is possible that reflux and aspiration maybe a precipitant or even a causal event in the pathogenesis of some pulmonary exacerbations. In support of this hypothesis, pH of exhaled breath condensate has been shown to be markedly lower in the acute phase of the exacerbations.
Whilst the effect of fundoplication in CF has not previously been studied, experiences in the context of lung transplantation have shown improvement in episodes of acute and chronic rejection and the serial lung function.[30, 31] These observations are again consistent with reflux and aspiration as a feature of pulmonary exacerbations, and have an important bearing in the context of CF, since many patients may progress to transplant assessment.
Technically, fundoplication is subtly more difficult in CF patients than in normal subjects with reflux. The tissues are generally more friable and edematous perhaps as a result of previous use of systemic steroids or as part of the systemic disease. In our patients, there were no operative or post-operative complications. Weight loss and dysphagia, recognised operative complications were trivial and short lived.
Our experience in the diagnosis and treatment of chronic cough, led us to the realisation that many patients with CF complain of a similar symptom profile indicative of reflux. In common with other reports, these patients have excessive acid reflux which we found to be unresponsive, in terms of cough, to medical anti-reflux therapy. Fundoplication produced a dramatic symptomatic improvement associated with a halving in the rate of pulmonary exacerbations. If this experience is replicated in larger studies, then reflux and aspiration may be demonstrated to be an important previously unrecognised mechanism of disease progression in CF.
Key points in history indicating the reflux origin of the cough
Hoarseness or a problem with the voice
Clearing the throat
Excess mucus in the throat, or drip down the back of the nose
Retching or vomiting when coughing
Cough on first lying down or bending over
Chest tightness or wheeze when coughing
Heartburn, indigestion, stomach acid coming up
A tickle in the throat, or a lump in the throat
Cough with eating (during or straight after meals)
Cough with certain foods
Cough when getting out of bed in the morning
Cough brought on by singing or speaking (for example, on the telephone)
Coughing during the day rather than night
A strange taste in the mouth
- Ratjen F, Doring G: Clinical manifestations of pulmonary disease in cystic fibrosis. Lancet. 2003, 22;361 (9358): 681-9. 10.1016/S0140-6736(03)12567-6.View ArticleGoogle Scholar
- Penketh AR, Wise A, Mearns MB, Hodson ME, Batten JC: Cystic fibrosis in adolescents and adults. Thorax. 1987, 42: 526-532. 10.1136/thx.42.7.526.PubMed CentralView ArticlePubMedGoogle Scholar
- Turck D, Michaud L, Wizla-Derambure N: Digestive diseases and nutrition in cystic fibrosis. Rev Prat. 2003, 53 (2): 151-7.PubMedGoogle Scholar
- Heine RG, Button BM, Olinsky A, Phelan PD, Catto-Smith AG: Gastro-oesophageal reflux in infants under 6 months with cystic fibrosis. Arch Dis Child. 1998, 78: 44-48. 10.1136/adc.78.1.44.PubMed CentralView ArticlePubMedGoogle Scholar
- Scott RB, O' Loughlin EV, Gall DG: Gastroesophageal reflux in patients with cystic fibrosis. J Pediatr. 1985, 106 (2): 223-7. 10.1016/S0022-3476(85)80291-2.View ArticlePubMedGoogle Scholar
- Brodzicki J, Trawińska-Bartnicka M, Korzon M: Frequency, consequences and pharmacological treatment of gastroesophageal reflux in children with cystic fibrosis. Med Sci Monit. 2002, 8 (7): CR529-37.PubMedGoogle Scholar
- Ledson MJ, Tran B, Walshaw MJ: Prevalence and mechanisms of gastro-oesophageal reflux in adult cystic fibrosis patients. J R Soc Med. 1998, 91: 7-9.PubMed CentralPubMedGoogle Scholar
- Everett CF, Morice AH: Clinical history in gastroesophageal cough. Respir Med. 2007, 101 (2): 345-8. 10.1016/j.rmed.2006.05.006.View ArticlePubMedGoogle Scholar
- Allen CJ, Anvari M: Does laparoscopic fundoplication provide long-term control of gastroesophageal reflux related cough?. Surg Endosc. 2004, 18 (4): 633-637. 10.1007/s00464-003-8821-6.View ArticlePubMedGoogle Scholar
- Fathi H, Brook H, Thompson R, Hunter V, Morice AH: Reproducibility and sensitivity of Hull Reflux Cough Questionnaire. Abstract presented in ERS. 2008Google Scholar
- Adhami T, Richter JE: Twenty-four hour pH monitoring in the assessment of esophageal function. Semin Thorac Cardiovasc Surg. 2001, 13 (3): 241-54. 10.1053/stcs.2001.25313.View ArticlePubMedGoogle Scholar
- Streets CG, DeMeester TR: Ambulatory 24-hour Esophageal pH Monitoring: Why, When, and What to Do. Journal of Clinical Gastroenterology. 2003, 37 (1): 14-22. 10.1097/00004836-200307000-00007.View ArticlePubMedGoogle Scholar
- Ford AC, Forman D, Moayyedi P, Morice AH: Cough in the community: A cross sectional survey and the relationship to gastrointestinal symptoms. Thorax. 2006, 61 (11): 975-979. 10.1136/thx.2006.060087.PubMed CentralView ArticlePubMedGoogle Scholar
- Hamutcu R, Francis J, Karakoc F, Bush a: Objective monitoring of cough in children with cystic fibrosis. Pediatr Pulmonol. 2002, 34: 331-5. 10.1002/ppul.10174.View ArticlePubMedGoogle Scholar
- Smith JA, Owen EC, Jones AM, Dodd ME, Webb K, Woodcock A: Objective measurement of cough during pulmonary exacerbations in adults with cystic fibrosis. Thorax. 2006, 61: 425-429. 10.1136/thx.2005.050963.PubMed CentralView ArticlePubMedGoogle Scholar
- Dent J, El-Serag HB, Wallander M-A, Johansson S: Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005, 54: 710-717. 10.1136/gut.2004.051821.PubMed CentralView ArticlePubMedGoogle Scholar
- Button BM, Roberts S, Kotsimbos T, Levvey BJ, Williams TJ, Bailey M, Snell GI, Wilson J: Gastroesophageal reflux (symptomatic and silent): A potentially significant problem in patient with cystic fibrosis before and after lung transplantation. J Heart Lung transplant. 2005, 24: 1522-29. 10.1016/j.healun.2004.11.312.View ArticlePubMedGoogle Scholar
- Blondeau K, Dupont L, Mertens V, Verleden G, Malfroot A, Vandenplas Y, Hauser B, Sifrim D: Gastroesophageal reflux and aspiration of gastric contents in adult patients with cystic fibrosis. doi:10.1136/gut.2007.146134Google Scholar
- Stringer DA, Sprigg A, Juodis E, et al: The association of cystic fibrosis, gastroesophageal reflux, and reduced pulmonary function. Can Assoc Radiol J. 1988, 39: 100-2.PubMedGoogle Scholar
- Gustafsson PM, Fransson SG, Kjellman NI, Tibbling L: Gastro-oesophageal reflux and severity of pulmonary disease in cystic fibrosis. Scand J Gastroenterol. 1991, 26 (5): 449-56. 10.3109/00365529108998565.View ArticlePubMedGoogle Scholar
- Dent J, Dodds WJ, Hogan WJ, Toouli J: Factors that influence induction of gastroesophageal reflux in normal human subjects. Dig Dis Sci. 1988, 33: 270-5. 10.1007/BF01535748.View ArticlePubMedGoogle Scholar
- Aronson BS, Marquis M: Care of the Adult Patient With Cystic Fibrosis. MEDSURG Nursing. 2004, 13 (3):Google Scholar
- Morice AH, Fontana GA, Belvisi MG, Birring SS, Chung KF, Dicpinigaitis PV, Kastelik JA, McGarvey LP, Smith JA, Tatar M, Widdicombe J: ERS guidelines on the assessment of cough. Eur Respir J. 2007, 29 (6): 1256-76. 10.1183/09031936.00101006. 17540788View ArticlePubMedGoogle Scholar
- Peghini PL, Katz PO, Castell DO: Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology. 1998, 115 (6): 1335-1339. 10.1016/S0016-5085(98)70010-1.View ArticlePubMedGoogle Scholar
- Morice AH, Menon MS, Murennan SA, Everett C, Wright C, Jackson J, Thompson R: Opiate therapy in chronic cough. Am J Respir Crit care Med. 2007, 175: 312-15. 10.1164/rccm.200607-892OC.View ArticlePubMedGoogle Scholar
- Weerts JM, Dallemagne B, Hamoir E, et al: Laparascopic Nissen fundoplication: detailed analysis of 132 patients. Surg Laparasc Endosc. 1993, 3: 359-64.Google Scholar
- Allen CJ, Anvari M: Gastro-esophageal reflux related cough and its response to laparoscopic fundoplication. Thorax. 1998, 53: 963-68.PubMed CentralView ArticlePubMedGoogle Scholar
- Mainie I, Tutuian R, Agrawal A, et al: Fundoplication eliminates chronic cough due to non-acid reflux identified by impedence pH monitoring. Thorax. 2005, 60: 521-523. 10.1136/thx.2005.040139.PubMed CentralView ArticlePubMedGoogle Scholar
- Tate S, MacGregor G, Davis M, Innes JA, Greening AP: Airways in cystic fibrosis are acidified: detection by exhaled breath condensate. Thorax. 2002, 57: 926-9. 10.1136/thorax.57.11.926.PubMed CentralView ArticlePubMedGoogle Scholar
- Cantu E, Appel JZ, Hartwig MG, Woreta H, Green C, Messier R: Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease. ANN Thorac Surg. 2004, 78: 1142-51. 10.1016/j.athoracsur.2004.04.044.View ArticlePubMedGoogle Scholar
- Davis RD, Lau CL, Eubanks S, Messier RH, Hadjilidis D, Steele MP, palmer SM: Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. J Thorac Cardio Surg. 2003, 3 (125): 533-42. 10.1067/mtc.2003.166.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.